The UK government has announced much-awaited reforms to its clinical trials framework, explaining how several existing provisions will be soon replaced with new legislation or guidance. The changes, the government says, will make it faster and easier to gain approval and to run clinical trials in the country.
UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU
Changes Represent Biggest Overhaul In UK Clinical Trials Regulation In Over 20 Years
The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.
More from United Kingdom
• By
The UK branded drug industry is calling for adjustments to be made to the UK voluntary scheme framework for branded medicines, after the payment rate increased to 22.9% for 2025. Meanwhile, the generics industry says the scheme is functioning “as intended” and opposes any changes.
• By
An initiative run by health technology appraisal (HTA) bodies in the US, Canada and England is looking at how non-traditional treatment benefits, such as the value of hope and scientific spillover, can inform appraisals and understanding of a product’s value.
• By
The UK’s medicines regulator is pressing on with clarifying its expectations on decentralized manufacturing of medicines.
• By
Payers and health technology assessment bodies in the Netherlands, Germany and Italy are either unwilling to use real-world data in assessments or cannot due to their existing frameworks, say representatives from Gilead Sciences and Autolus Therapeutics.